Company / Cash & Equivalents
NeoGenomics Laboratories, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$159.6M
FY2025
5-year range
$159.6M / $367.0M
FY2021-FY2025
Trend
-56.5%
vs FY2024
Sector context
#93 of 148
Health Care
What the data says
At $160M, NeoGenomics Laboratories, Inc.'s cash & equivalents ranks #93 of 148 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $10M in FY2018 to $367M in FY2024.
Based on SEC 10-K filings.
$160M in FY2025 with a 5-year CAGR of -6.9%.
Declined from $342M to $160M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -15.4%
- 5-Year CAGR
- -6.9%
- 10-Year CAGR
- -
Sector benchmark
#93 of 148 in Health CareTop 63% of 148This company $159.6M Sector average $1.2B
▼
-86.4% below sector average
Key checks
Key Insights
- 5-year CAGR of -6.9%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 56.5% year-over-year.
- Ranks #93 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $159.6M | -56.5% |
| FY2024 | $367.0M | +7.2% |
| FY2023 | $342.5M | +30.1% |
| FY2022 | $263.2M | -16.9% |
| FY2021 | $316.8M | +38.5% |
| FY2020 | $228.7M | +32.2% |
| FY2019 | $173.0M | +1663.5% |
| FY2018 | $9.8M | -23.5% |
| FY2017 | $12.8M | +2.4% |
| FY2016 | $12.5M | -46.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026